Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium

Circulation

Volumn 113, Issue 14, 2006, Pages 1787-1798

  Itoh, Seigo ^a   Ding, Bo ^a   Shishido, Tetsuro ^a   Lerner Marmarosh, Nicole ^a   Wang, Nadan ^a   Maekawa, Naoya ^a   Berk, Bradford C ^a   Takeishi, Yasuchika ^b   Yan, Chen ^a   Blaxall, Burns C ^a   Abe, Jun Ichi ^a,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b YAMAGATA UNIVERSITY   (Japan)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Angiotensin; Diabetes mellitus; Ischemia; Renin; Signal transduction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CAPTOPRIL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIKREIN; LACTATE DEHYDROGENASE; MESSENGER RNA; OLMESARTAN; PRORENIN; PRORENIN CONVERTING ENZYME; RAS PROTEIN; RENIN; S6 KINASE; UNCLASSIFIED DRUG; KLK26 PROTEIN, MOUSE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME RELEASE; HEART FAILURE; HEART INFARCTION SIZE; HEART INJURY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RATE; HEMODYNAMICS; INCIDENCE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; WILD TYPE; ANIMAL; CARDIOMEGALY; CARDIOMYOPATHY; DIABETIC ANGIOPATHY; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; HEMODYNAMIC PROCESSES; KALLIKREINS; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIUM; RENIN-ANGIOTENSIN SYSTEM; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646672652     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.578278     Document Type: Article

References (48)

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
2. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997;96:4239-4245.
3. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction: Trace Study Group. J Am Coll Cardiol. 1999;34:83-89.
4. Al-Merani SA, Brooks DP, Chapman BJ, Munday KA. The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat. J Physiol. 1978;278:471-490.
5. Chapman BJ, Brooks DP, Munday KA. Half-life of angiotensin II in the conscious and barbiturate-anaesthetized rat. Br J Anaesth. 1980;52:389-393.
6. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;412:86-90.
7. Nakayama T, Izumi Y, Soma M, Kanmatsuse K. Adrenal renin-angiotensin- aldosterone system in streptozotocin-diabetic rats. Horm Metab Res. 1998;30:12-15.
8. Cronin CC, Barry D, Crowley B, Ferriss JB. Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus. Diabet Med. 1995;12:809-815.
9. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, Passan DR, Williams GH, Hollenberg NK. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10:2382-2391.
10. King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T, Xia P. Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes. 1996;3:8105-8108.
11. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C-β inhibition. Am J Kidney Dis. 2003;42:456-465.
12. Takeishi Y, Chu G, Kirkpatrick DM, Li Z, Wakasaki H, Kranias EG, King GL, Walsh RA. In vivo phosphorylation of cardiac troponin I by protein kinase Cβ2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. J Clin Invest. 1998;102:72-78.
13. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA. Transgenic overexpression of constitutively active protein kinase C-ε causes concentric cardiac hypertrophy. Circ Res. 2000;86:1218-1223.
14. Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC. Reactive oxygen species activate p90 ribosomal S6 kinase via fyn and ras. J Biol Chem. 2000;275:1739-1748.
15. Itoh S, Ding B, Bains CP, Wang N, Takeishi Y, Jalili T, King GL, Walsh RA, Yan C, Abe J. Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C-β - mediated cardiac troponin I phosphorylation. J Biol Chem. 2005;280:24135-24142.
16. Ghoda L, Lin X, Greene WC. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. J Biol Chem. 1997;272:21281-21288.
17. Chen RH, Chung J, Blenis J. Regulation of pp90rsk phosphorylation and 86 phosphotransferase activity in Swiss 3T3 cells by growth factor-, phorbol ester-, and cyclic AMP-mediated signal transduction. Mol Cell Biol. 1991;11:1861-1867.
18. Fisher TL, Blenis J. Evidence for two catalytically active kinase domains in pp90rsk. Mol Cell Biol. 1996;16:1212-1219.
19. Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 1996;273:959-963.
20. Bell DS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18:708-714.
21. Cameron SJ, Malik S, Akaike M, Lerner-Marmarosh N, Yan C, Lee JD, Abe J, Yang J. Regulation of epidermal growth factor - induced connexin 43 gap junction communication by big mitogen-activated protein kinase1/ERK5 but not ERK1/2 kinase activation. J Biol Chem. 2003;278:18682-18688.
22. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II - forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
23. Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996;27:7-13.
24. Nakano A, Miura T, Ura N, Suzuki K, Shimamoto K. Role of the angiotensin II type 1 receptor in preconditioning against infarction. Coron Artery Dis. 1997;8:343-350.
25. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation. 1999;100:2093-2099.
26. Varma N, Morgan JP, Apstein CS. Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate. Am J Physiol Heart Circ Physiol. 2003;284:H758-H771.
27. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation. 2005;111:2469-2476.
28. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000;105:1243-1252.
29. + exchanger isoform 1 (NHE1) - mediated cardiac ischemia-reperfusion (I/R) injury. Circulation. 2004;110(suppl III):III-67. Abstract.
30. Ford WR, Clanachan AS, Lopaschuk GD, Schulz R, Jugdutt BI. Intrinsic ANG II type 1 receptor stimulation contributes to recovery of postischemic mechanical function. Am J Physiol. 1998:274(pt 2):H1524-H1531.
31. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol. 1998;93(suppl 2):85-91.
32. Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation. 1997;96:220-226.
33. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial; the SAVE Investigators. N Engl J Med. 1992;327:669-677.
34. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1166-1174.
35. Morris BJ, Reid IA. A 'renin-like' enzymatic action of cathepsin D and the similarity in subcellular distributions of 'renin-like' activity and cathepsin D in the midbrain of dogs. Endocrinology. 1978;103:1289-1296.
36. Dzau VJ, Gonzalez D, Kaempfer C, Dubin D, Wintroub BU. Human neutrophils release serine proteases capable of activating prorenin. Circ Res. 1987;60:595-601.
37. Derkx FH, Tan-Tjiong HL, Man in't Veld AJ, Schalekamp MP, Schalekamp MA. Activation of inactive plasma renin by tissue kallikreins. J Clin Endocrinol Metab. 1979;49:765-769.
38. Kim WS, Nakayama K, Murakami K. The presence of two types of prorenin converting enzymes in the mouse submandibular gland. FEBS Lett. 1991;293:142-144.
39. Kim WS, Nakayama K, Nakagawa T, Kawamura Y, Haraguchi K, Murakami K. Mouse submandibular gland prorenin-converting enzyme is a member of glandular kallikrein family. J Biol Chem. 1991;266:19283-19287.
40. Olsson AY, Lundwall A. Organization and evolution of the glandular kallikrein locus in Mus musculus. Biochem Biophys Res Commun. 2002;299:305-311.
41. Diamandis EP, Yousef GM, Olsson AY. An update on human and mouse glandular kallikreins. Clin Biochem. 2004;37:258-260.
42. Clark DE, Errington TM, Smith JA, Frierson HF Jr, Weber MJ, Lannigan DA. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 2005;65:3108-3116.
43. Leckie BJ, Morton JJ. Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios. J Hum Hypertens. 1995;9:493-496.
44. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem. 2002;48:1198-1205.
45. Peters J, Farrenkopf R, Clausmeyer S, Zimmer J, Kantachuvesiri S, Sharp MG, Mullins JJ. Functional significance of prorenin internalization in the rat heart. Circ Res. 2002;90:1135-1141.
46. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol. 2004;286:F1039-F1045.
47. Luetscher JA, Kraemer FB, Wilson DM. Prorenin and vascular complications of diabetes. Am J Hypertens. 1989;2(pt 1):382-386.
48. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16:592-599.